Jeffrey N. Joyce - Publications

Affiliations: 
Arizona State University, Tempe, AZ, United States 
Area:
Neuroscience Biology

111 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Experimental Neurology. 225: 210-8. PMID 20599975 DOI: 10.1016/j.expneurol.2010.06.017  0.56
2010 Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, Nehama D, Rajadas J, Longo FM. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. The Journal of Clinical Investigation. 120: 1774-85. PMID 20407211 DOI: 10.1172/JCI41356  0.56
2010 Iarkov AV, Der TC, Joyce JN. Age-related differences in MK-801 induced behaviors in dopamine D3 receptor knock out mice. European Journal of Pharmacology. 627: 177-84. PMID 19909735 DOI: 10.1016/j.ejphar.2009.11.012  0.56
2010 Yarkov AV, Der TC, Joyce JN. Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor. European Journal of Pharmacology. 627: 167-72. PMID 19900441 DOI: 10.1016/j.ejphar.2009.10.068  0.56
2009 Kufahl PR, Zavala AR, Singh A, Thiel KJ, Dickey ED, Joyce JN, Neisewander JL. c-Fos expression associated with reinstatement of cocaine-seeking behavior by response-contingent conditioned cues. Synapse (New York, N.Y.). 63: 823-35. PMID 19533625 DOI: 10.1002/syn.20666  0.56
2009 Duka T, Duka V, Joyce JN, Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 2820-30. PMID 19369384 DOI: 10.1096/fj.08-120410  0.56
2009 Mastroeni D, Grover A, Leonard B, Joyce JN, Coleman PD, Kozik B, Bellinger DL, Rogers J. Microglial responses to dopamine in a cell culture model of Parkinson's disease. Neurobiology of Aging. 30: 1805-17. PMID 18325635 DOI: 10.1016/j.neurobiolaging.2008.01.001  0.56
2008 Zavala AR, Osredkar T, Joyce JN, Neisewander JL. Upregulation of Arc mRNA expression in the prefrontal cortex following cue-induced reinstatement of extinguished cocaine-seeking behavior. Synapse (New York, N.Y.). 62: 421-31. PMID 18361437 DOI: 10.1002/syn.20502  0.56
2008 Bychkov ER, Gurevich VV, Joyce JN, Benovic JL, Gurevich EV. Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia Neurobiology of Aging. 29: 379-396. PMID 17125886 DOI: 10.1016/j.neurobiolaging.2006.10.012  0.56
2007 Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain : a Journal of Neurology. 130: 2607-15. PMID 17698496 DOI: 10.1093/brain/awm191  0.56
2007 Joyce JN, Millan MJ. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Current Opinion in Pharmacology. 7: 100-5. PMID 17174156 DOI: 10.1016/j.coph.2006.11.004  0.56
2006 Yoshimoto K, Nishimura A, Hattori H, Joyce JN, Yoshida T, Hioki C, Kogure A, Ueda S. In vivo brain microdialysis studies on the striatal dopamine and serotonin release in zitter mutant rats. Mechanisms of Ageing and Development. 127: 628-32. PMID 16620918 DOI: 10.1016/j.mad.2006.02.008  0.56
2006 Nakadate K, Noda T, Sakakibara SI, Kumamoto K, Matsuura T, Joyce JN, Ueda S. Progressive dopaminergic neurodegeneration of substantia nigra in the zitter mutant rat Acta Neuropathologica. 112: 64-73. PMID 16609850 DOI: 10.1007/s00401-006-0058-8  0.56
2005 Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today. 10: 917-25. PMID 15993811 DOI: 10.1016/S1359-6446(05)03491-4  0.56
2005 Ueda S, Sakakibara S, Nakadate K, Noda T, Shinoda M, Joyce JN. Degeneration of dopaminergic neurons in the substantia nigra of zitter mutant rat and protection by chronic intake of Vitamin E. Neuroscience Letters. 380: 252-6. PMID 15862896 DOI: 10.1016/j.neulet.2005.01.053  0.56
2004 Presgraves SP, Borwege S, Millan MJ, Joyce JN. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Experimental Neurology. 190: 157-70. PMID 15473989 DOI: 10.1016/j.expneurol.2004.06.021  0.56
2004 Joyce JN, Woolsey C, Ryoo H, Borwege S, Hagner D. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. Bmc Biology. 2: 22. PMID 15473914 DOI: 10.1186/1741-7007-2-22  0.56
2004 Dluzen DE, McDermott JL, Anderson LI, Kucera J, Joyce JN, Osredkar T, Walro JM. Age-related changes in nigrostriatal dopaminergic function are accentuated in +/- brain-derived neurotrophic factor mice. Neuroscience. 128: 201-8. PMID 15450367 DOI: 10.1016/j.neuroscience.2004.06.032  0.56
2004 Presgraves SP, Ahmed T, Borwege S, Joyce JN. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotoxicity Research. 5: 579-98. PMID 15111235 DOI: 10.1007/BF03033178  0.56
2004 Neisewander JL, Fuchs RA, Tran-Nguyen LT, Weber SM, Coffey GP, Joyce JN. Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 1479-87. PMID 15100700 DOI: 10.1038/sj.npp.1300456  0.56
2004 Beach TG, Walker DG, Sue LI, Newell A, Adler CC, Joyce JN. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. Journal of Neuropathology and Experimental Neurology. 63: 329-37. PMID 15099023  0.56
2004 Joyce JN, Der TC, Renish L, Osredkar T, Hagner D, Reploge M, Sakakibara S, Ueda S. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment. Experimental Neurology. 187: 178-89. PMID 15081599 DOI: 10.1016/j.expneurol.2004.01.012  0.56
2004 Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. The Journal of Pharmacology and Experimental Therapeutics. 309: 921-35. PMID 14978195 DOI: 10.1124/jpet.103.062414  0.56
2004 Joyce JN, Renish L, Osredkar T, Walro JM, Kucera J, Dluzen DE. Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations. Synapse (New York, N.Y.). 52: 11-9. PMID 14755628 DOI: 10.1002/syn.10309  0.56
2003 Yarkov AV, Hanger D, Reploge M, Joyce JN. Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice. Pharmacology, Biochemistry, and Behavior. 76: 551-62. PMID 14643855 DOI: 10.1016/j.pbb.2003.09.011  0.56
2003 Joyce JN, Presgraves S, Renish L, Borwege S, Osredkar T, Hagner D, Replogle M, PazSoldan M, Millan MJ. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole. Experimental Neurology. 184: 393-407. PMID 14637109 DOI: 10.1016/S0014-4886(03)00353-4  0.56
2002 Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism & Related Disorders. 9: 103-10. PMID 12473400 DOI: 10.1016/S1353-8020(02)00012-3  0.56
2002 Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, Adler CH. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: Role of D3 and not D2 receptors Brain Research. 955: 138-152. PMID 12419530 DOI: 10.1016/S0006-8993(02)03396-6  0.56
2001 Joyce JN. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs Pharmacology and Therapeutics. 90: 231-259. PMID 11578658 DOI: 10.1016/S0163-7258(01)00139-5  0.56
2001 Gurevich EV, Robertson RT, Joyce JN. Thalamo-cortical afferents control transient expression of the dopamine D(3) receptor in the rat somatosensory cortex. Cerebral Cortex (New York, N.Y. : 1991). 11: 691-701. PMID 11459759  0.56
2001 Joyce JN, Ryoo H, Gurevich EV, Adler C, Beach T. Ventral striatal D3 receptors and Parkinson's Disease Parkinsonism and Related Disorders. 7: 225-230. DOI: 10.1016/S1353-8020(00)00060-2  0.56
2000 Gurevich EV, Kordower JH, Joyce JN. Ontogeny of the dopamine D2 receptor mRNA expressing cells in the human hippocampal formation and temporal neocortex Journal of Chemical Neuroanatomy. 20: 307-325. PMID 11207428 DOI: 10.1016/S0891-0618(00)00108-3  0.56
2000 Joyce JN, Yoshimoto K, Ueda S. The zitter mutant rat exhibits loss of D3 receptors with degeneration of the dopamine system Neuroreport. 11: 2173-2175. PMID 10923665  0.56
2000 Gurevich EV, Joyce JN. Dopamine D3 receptor is selectively and transiently expressed in the developing whisker barrel cortex of the rat Journal of Comparative Neurology. 420: 35-51. PMID 10745218 DOI: 10.1002/(SICI)1096-9861(20000424)420:1<35::AID-CNE3>3.0.CO;2-K  0.56
1999 Joyce JN, Gurevich EV. D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics Annals of the New York Academy of Sciences. 877: 595-613. PMID 10415673 DOI: 10.1111/j.1749-6632.1999.tb09291.x  0.56
1999 Ma SY, Ciliax BJ, Stebbins G, Jaffar S, Joyce JN, Cochran EJ, Kordower JH, Mash DC, Levey AI, Mufson EJ. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. The Journal of Comparative Neurology. 409: 25-37. PMID 10363709 DOI: 10.1002/(SICI)1096-9861(19990621)409:1<25::AID-CNE3>3.0.CO;2-E  0.56
1999 Neal-Beliveau BS, Joyce JN. Timing: A critical determinant of the functional consequences of neonatal 6-OHDA lesions Neurotoxicology and Teratology. 21: 129-140. PMID 10192273 DOI: 10.1016/S0892-0362(98)00044-0  0.56
1999 Gurevich EV, Himes JW, Joyce JN. Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and Islands of Calleja Journal of Pharmacology and Experimental Therapeutics. 289: 587-598. PMID 10087054  0.56
1999 Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain comparison with D2 receptor expressing neurons Neuropsychopharmacology. 20: 60-80. PMID 9885786 DOI: 10.1016/S0893-133X(98)00066-9  0.56
1999 Joyce JN, Gurevich EV. Dopamine D3 receptors: From anatomy to neuropsychiatry Neuroscience News. 2: 11-21.  0.56
1998 Thomas WS, Neal-Beliveau BS, Joyce JN. There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum Developmental Brain Research. 111: 99-106. PMID 9804909 DOI: 10.1016/S0165-3806(98)00126-6  0.56
1998 Joyce JN, Murray AM, Hurtig HI, Gottlieb GL, Trojanowski JQ. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 19: 472-80. PMID 9803423 DOI: 10.1016/S0893-133X(98)00044-X  0.56
1998 Ryoo HL, Pierrotti D, Joyce JN. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease Movement Disorders. 13: 788-797. PMID 9756147 DOI: 10.1002/mds.870130506  0.56
1998 Neal-Beliveau BS, Joyce JN. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development Developmental Psychobiology. 32: 313-326. PMID 9589220 DOI: 10.1002/(SICI)1098-2302(199805)32:4<313::AID-DEV6>3.0.CO;2-Q  0.56
1998 Joyce JN, Myers AJ, Gurevich E. Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease. Brain Research. 784: 7-17. PMID 9518532 DOI: 10.1016/S0006-8993(97)01005-6  0.56
1998 Rioux L, Nissanov J, Joyce JN. Increased number of [125I] BH-substance P receptors in schizophrenia Progress in Neuro-Psychopharmacology and Biological Psychiatry. 22: 1295-1299. DOI: 10.1016/S0278-5846(98)00084-0  0.56
1997 Gurevich EV, Kordower J, Joyce JN. Dopamine D2 receptor mRNA is expressed in maturing neurons of the human hippocampal and subicular fields Neuroreport. 8: 3605-3610. PMID 9427335 DOI: 10.1097/00001756-199711100-00037  0.56
1997 Joyce JN, Smutzer G, Whitty CJ, Myers A, Bannon MJ. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 12: 885-97. PMID 9399211 DOI: 10.1002/mds.870120609  0.56
1997 Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study Biological Psychiatry. 42: 529-545. PMID 9376449 DOI: 10.1016/S0006-3223(97)00321-1  0.56
1997 Joyce JN, Goldsmith SG, Gurevich EV. Limbic circuits and monoamine receptors: Dissecting the effects of antipsychotics from disease processes Journal of Psychiatric Research. 31: 197-217. PMID 9278186 DOI: 10.1016/S0022-3956(96)00043-X  0.56
1997 Goldsmith SK, Shapiro RM, Joyce JN. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia: A postmortem study Archives of General Psychiatry. 54: 649-658. PMID 9236549  0.56
1997 Joyce JN, Meador-Woodruff JH. Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 16: 375-84. PMID 9165493 DOI: 10.1016/S0893-133X(96)00276-X  0.56
1997 Rioux L, Frohna PA, Joyce JN, Schneider JS. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of Parkinsonian monkeys Movement Disorders. 12: 148-158. PMID 9087972 DOI: 10.1002/mds.870120204  0.56
1997 Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Archives of General Psychiatry. 54: 225-32. PMID 9075463 DOI: 10.1001/archpsyc.1997.01830150047009  0.56
1997 Frohna PA, Neal-Beliveau BS, Joyce JN. Delayed plasticity of the mesolimbic dopamine system following neonatal 6-OHDA lesions Synapse. 25: 293-305. PMID 9068128 DOI: 10.1002/(SICI)1098-2396(199703)25:3<293::AID-SYN9>3.0.CO;2-6  0.56
1996 Joyce JN, Frohna PA, Neal-Beliveau BS. Functional and molecular differentiation of the dopamine system induced by neonatal denervation Neuroscience and Biobehavioral Reviews. 20: 453-486. PMID 8880735 DOI: 10.1016/0149-7634(95)00025-9  0.56
1996 Goldsmith SK, Joyce JN. Dopamine D2 receptors are organized in bands in normal human temporal cortex Neuroscience. 74: 435-451. PMID 8865195 DOI: 10.1016/0306-4522(96)00132-7  0.56
1996 Solbrig MV, Koob GF, Joyce JN, Lipkin WI. A neural substrate of hyperactivity in Borna disease: Changes in brain dopamine receptors Virology. 222: 332-338. PMID 8806517 DOI: 10.1006/viro.1996.0430  0.56
1996 Gurevich EV, Joyce JN. Comparison of [3H]paroxetine and [3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain Neuropsychopharmacology. 14: 309-323. PMID 8703300 DOI: 10.1016/0893-133X(95)00139-5  0.56
1995 Goldsmith SK, Joyce JN. Alterations in hippocampal mossy fiber pathway in Schizophrenia and Alzheimer' s disease Biological Psychiatry. 37: 122-126. PMID 7718676 DOI: 10.1016/0006-3223(94)00200-M  0.56
1995 Frohna PA, Rothblat DS, Joyce JN, Schneider JS. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism Synapse. 19: 46-55. PMID 7709343 DOI: 10.1002/syn.890190107  0.56
1995 Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Annals of Neurology. 37: 300-12. PMID 7695230 DOI: 10.1002/ana.410370306  0.56
1995 Frohna PA, Neal-Beliveau BS, Joyce JN. Neonatal 6-hydroxydopamine lesions lead to opposing changes in the levels of dopamine receptors and their messenger RNAs Neuroscience. 68: 505-518. PMID 7477961 DOI: 10.1016/0306-4522(95)00155-C  0.56
1994 Murray AM, Ryoo HL, Gurevich E, Joyce JN. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proceedings of the National Academy of Sciences of the United States of America. 91: 11271-5. PMID 7972046 DOI: 10.1073/pnas.91.23.11271  0.56
1994 UÅ‚as J, Weihmuller FB, Brunner LC, Joyce JN, Marshall JF, Cotman CW. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 14: 6317-24. PMID 7965038  0.56
1994 Lexow N, Joyce JN, Kim SJ, Phillips J, Casanova MF, Bird ED, Kleinman JE, Winokur A. Alterations in TRH receptors in temporal lobe of schizophrenics: a quantitative autoradiographic study. Synapse (New York, N.Y.). 18: 315-27. PMID 7886624 DOI: 10.1002/syn.890180407  0.56
1994 Goldsmith SK, Joyce JN. Dopamine D2 receptor expression in hippocampus and parahippocampal cortex of rat, cat, and human in relation to tyrosine hydroxylase‐immunoreactive fibers Hippocampus. 4: 354-373. PMID 7842057 DOI: 10.1002/hipo.450040318  0.56
1994 Ryoo HL, Joyce JN. Loss of dopamine D2 receptors varies along the rostrocaudal axis of the hippocampal complex in Alzheimer's disease Journal of Comparative Neurology. 348: 94-110. PMID 7814686  0.56
1994 Joyce JN. Response Neuropsychopharmacology. 11: 145-147. DOI: 10.1038/npp.1994.62  0.56
1993 Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 8: 315-36. PMID 8512620 DOI: 10.1038/npp.1993.32  0.56
1993 Joyce JN. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases Brain Research. 600: 156-160. PMID 8422582 DOI: 10.1016/0006-8993(93)90414-I  0.56
1993 Neal-Beliveau BS, Joyce JN, Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. The Journal of Pharmacology and Experimental Therapeutics. 265: 207-17. PMID 8386235  0.56
1993 Joyce JN, Kaeger C, Ryoo H, Goldsmith S. Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer's disease Neuroscience Letters. 154: 171-174. PMID 8361636 DOI: 10.1016/0304-3940(93)90199-U  0.56
1993 Neal-Beliveau BS, Joyce JN. D1 and D2 dopamine receptors do not up-regulate in response to neonatal intrastriatal 6-hydroxydopamine lesions Neuroscience Letters. 160: 77-80. PMID 8247338 DOI: 10.1016/0304-3940(93)90917-A  0.56
1993 Frohna PA, Neal-Beliveau BS, Joyce JN. Neonatal 6-OHDA lesions upregulate adult expression of tyrosine hydroxylase mRNA Neuroreport. 4: 1095-1098. PMID 8106005  0.56
1993 Joyce JN. The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine Psychopharmacology. 112. PMID 7831438 DOI: 10.1007/BF02245004  0.56
1993 Rioux L, Joyce JN. Substance P receptors are differentially affected in Parkinson's and Alzheimer's disease Journal of Neural Transmission - Parkinson's Disease and Dementia Section. 6: 199-210. PMID 7510109 DOI: 10.1007/BF02260922  0.56
1992 Murray AM, Ryoo H, Joyce JN. Visualization of dopamine D3-like receptors in human brain with [125I]epidepride. European Journal of Pharmacology. 227: 443-5. PMID 1359976 DOI: 10.1016/0922-4106(92)90164-Q  0.56
1992 Neal BS, Joyce JN. Neonatal 6-OHDA lesions differentially affect striatal D1 and D2 receptors Synapse. 11: 35-46. PMID 1351321 DOI: 10.1002/syn.890110106  0.56
1992 Joyce JN. Monoamine receptors, limbic pathology and schizophrenia Clinical Neuropharmacology. 15. PMID 1323403  0.56
1992 Kleinman JE, Laruelle M, Joyce JN, Casanova MF. Abnormalities of serotonergic neural transmission in prefrontal cortex in schizophrenia. Clinical Neuropharmacology. 15: 397A-398A. PMID 1323396  0.56
1992 Joyce JN, Lexow N, Kim SJ, Artymyshyn R, Senzon S, Lawrence D, Cassanova MF, Kleinman JE, Bird ED, Winokur A. Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: alterations in limbic regions of schizophrenics. Synapse (New York, N.Y.). 10: 228-46. PMID 1313605 DOI: 10.1002/syn.890100306  0.56
1991 Joyce JN. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment Experimental Neurology. 113: 277-290. PMID 1833220 DOI: 10.1016/0014-4886(91)90017-7  0.56
1991 Joyce JN. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system Experimental Neurology. 113: 261-276. PMID 1833219 DOI: 10.1016/0014-4886(91)90016-6  0.56
1991 Rao PA, Molinoff PB, Joyce JN. Ontogeny of dopamine D1 and D2 receptor subtypes in rat basal ganglia: a quantitative autoradiographic study. Brain Research. Developmental Brain Research. 60: 161-77. PMID 1832594 DOI: 10.1016/0165-3806(91)90045-K  0.56
1991 Neal BS, Joyce JN. Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development Developmental Brain Research. 60: 105-113. PMID 1832593 DOI: 10.1016/0165-3806(91)90038-K  0.56
1991 Joyce JN, Janowsky A, Neve KA. Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain. The Journal of Pharmacology and Experimental Therapeutics. 257: 1253-63. PMID 1828505  0.56
1990 Lowenstein PR, Joyce JN, Coyle JT, Marshall JF. Striosomal organization of cholinergic and dopaminergic uptake sites and cholinergic M1 receptors in the adult human striatum: a quantitative receptor autoradiographic study. Brain Research. 510: 122-6. PMID 2322836 DOI: 10.1016/0006-8993(90)90736-U  0.56
1990 Joyce JN, Hurtig H. Differential regulation of striatal dopamine D1 and D2 receptor systems in Parkinson's disease and effects of adrenal medullary transplant Progress in Brain Research. 82: 699-706. PMID 2290973  0.56
1989 Joyce JN, Gibbs RB, Cotman CW, Marshall JF. Regulation of muscarinic receptors in hippocampus following cholinergic denervation and reinnervation by septal and striatal transplants. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 9: 2776-91. PMID 2769366  0.56
1989 Marshall JF, Navarrete R, Joyce JN. Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis. Brain Research. 493: 247-57. PMID 2527583 DOI: 10.1016/0006-8993(89)91160-8  0.56
1988 Marshall JF, Joyce JN. Basal ganglia dopamine receptor autoradiography and age-related movement disorders. Annals of the New York Academy of Sciences. 515: 215-25. PMID 3364885 DOI: 10.1111/j.1749-6632.1988.tb32988.x  0.56
1988 Joyce JN, Gibbs RB, Cotman CW, Marshall JF. Regulation of acetylcholine muscarinic receptors by embryonic septal grafts showing cholinergic innervation of host hippocampus. Progress in Brain Research. 78: 109-16. PMID 3247416  0.56
1988 Joyce JN, Lexow N, Bird E, Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia Synapse. 2: 546-557. PMID 2973147 DOI: 10.1002/syn.890020511  0.56
1987 Rhodes KJ, Joyce JN, Sapp DW, Marshall JF. [3H]hemicholinium-3 binding in rabbit striatum: correspondence with patchy acetylcholinesterase staining and a method for quantifying striatal compartments. Brain Research. 412: 400-4. PMID 3607475 DOI: 10.1016/0006-8993(87)91151-6  0.56
1987 Joyce JN, Marshall JF. Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen: localization to intrinsic neurons and not to neocortical afferents. Neuroscience. 20: 773-95. PMID 2955247 DOI: 10.1016/0306-4522(87)90240-5  0.56
1986 Joyce JN, Sapp DW, Marshall JF. Human striatal dopamine receptors are organized in compartments. Proceedings of the National Academy of Sciences of the United States of America. 83: 8002-6. PMID 2945207  0.56
1986 Joyce JN, Marshall JF, Bankiewicz KS, Kopin IJ, Jacobowitz DM. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Research. 382: 360-4. PMID 2944565 DOI: 10.1016/0006-8993(86)91345-4  0.56
1986 Joyce JN, Loeschen SK, Sapp DW, Marshall JF. Age-related regional loss of caudate-putamen dopamine receptors revealed by quantitative autoradiography. Brain Research. 378: 158-63. PMID 2943360 DOI: 10.1016/0006-8993(86)90298-2  0.56
1986 Van Hartesveldt C, Joyce JN. Effects of estrogen on the basal ganglia. Neuroscience and Biobehavioral Reviews. 10: 1-14. PMID 2871534 DOI: 10.1016/0149-7634(86)90029-1  0.56
1985 Rowland N, Joyce JN, Bellush LL. Stereotyped behavior and diabetes mellitus in rats: Reduced behavioral effects of amphetamine and apomorphine and reduced in vivo brain binding of [3H]spiroperidol Behavioral Neuroscience. 99: 831-841. PMID 3916385 DOI: 10.1037//0735-7044.99.5.831  0.56
1985 Joyce JN, Loeschen SK, Marshall JF. Dopamine D-2 receptors in rat caudate-putamen: the lateral to medial gradient does not correspond to dopaminergic innervation. Brain Research. 338: 209-18. PMID 3161583 DOI: 10.1016/0006-8993(85)90149-0  0.56
1985 Joyce JN, Marshall JF. Striatal topography of D-2 receptors correlates with indexes of cholinergic neuron localization. Neuroscience Letters. 53: 127-31. PMID 3157889 DOI: 10.1016/0304-3940(85)90108-9  0.56
1984 Joyce JN, van Hartesveldt C. Rotation and postural deviation elicited by microinjections of dopamine into medial and lateral regions of dorsal striatum. Pharmacology, Biochemistry, and Behavior. 21: 979-81. PMID 6522422  0.56
1984 Joyce JN, Montero E, Van Hartesveldt C. Dopamine-mediated behaviors: characteristics of modulation by estrogen. Pharmacology, Biochemistry, and Behavior. 21: 791-800. PMID 6514769  0.56
1984 Joyce JN, Van Hartesveldt C. Estradiol application to one striatum produces postural deviation to systemic apomorphine. Pharmacology, Biochemistry, and Behavior. 20: 575-81. PMID 6374687 DOI: 10.1016/0091-3057(84)90307-1  0.56
1984 Joyce JN, Van Hartesveldt C. Behaviors induced by intrastriatal dopamine vary independently across the estrous cycle. Pharmacology, Biochemistry, and Behavior. 20: 551-7. PMID 6374686 DOI: 10.1016/0091-3057(84)90304-6  0.56
1983 Joyce JN, Davis RE, Van Hartesveldt C. Systemic apomorphine reverses intrastriatal dopamine-induced contralateral deviation. European Journal of Pharmacology. 87: 283-9. PMID 6840191 DOI: 10.1016/0014-2999(83)90339-4  0.56
1983 Joyce JN. Multiple dopamine receptors and behavior Neuroscience and Biobehavioral Reviews. 7: 227-256. PMID 6136014 DOI: 10.1016/0149-7634(83)90017-9  0.56
1982 Joyce JN, Smith RL, van Hartesveldt C. Estradiol suppresses then enhances intracaudate dopamine-induced contralateral deviation. European Journal of Pharmacology. 81: 117-22. PMID 7117364 DOI: 10.1016/0014-2999(82)90608-2  0.56
1981 Joyce JN, Davis RE, Van Hartesveldt C. Behavioral effects of unilateral dopamine injection into dorsal or ventral striatum. European Journal of Pharmacology. 72: 1-10. PMID 7196334 DOI: 10.1016/0014-2999(81)90290-9  0.56
Show low-probability matches.